Single-Cell Blood Profiles Predicted Leukemia Drug Response From Changes Seen Within Three Hours
Health

Single-Cell Blood Profiles Predicted Leukemia Drug Response From Changes Seen Within Three Hours

Researchers profiled 44 million cells from 81 people with newly diagnosed chronic myeloid leukemia before and shortly after their first targeted-therapy dose. Early immune and signaling patterns predicted molecular response during the following year, but the analyses were exploratory, cohorts were small and clinical decision-making was not tested.

NewTqnia Health Desk Updated 4 min read
Single-Cell Blood Profiles Predicted Leukemia Drug Response From Changes Seen Within Three Hours

A blood sample taken only one to three hours after the first targeted-therapy dose may contain clues about how chronic myeloid leukemia will respond over the following year. Researchers used mass cytometry to map immune cells and intracellular signaling in two clinical-trial cohorts, then linked those early patterns to later molecular response.

The 30-second summary

  • What happened? Researchers profiled blood before and shortly after the first dose of dasatinib or nilotinib in 81 newly diagnosed patients.
  • Why does it matter? Early signaling changes could eventually help identify people who need closer monitoring or a different treatment strategy.
  • What is the catch? The biomarker analyses were exploratory, the cohorts were small, and no treatment decision was made from the predictions.

From the first dose to a 12-month response

The study, published in Signal Transduction and Targeted Therapy on 18 November 2026, used samples from two existing trials. Thirty-two patients in NordCML007 received dasatinib, while 49 patients in ENEST1st received nilotinib. Blood was collected before treatment and approximately one hour after dasatinib or three hours after nilotinib, matching the drugs' typical time to peak concentration.

Key number: The team analyzed about 44 million individual cells from 229 patient blood samples and identified 37 immune-cell populations.

Each sample was measured with a panel of 43 metal-tagged antibodies. This let the researchers examine both the composition of the immune system and phosphorylation signals inside cells, including pathways related to BCR::ABL1, the abnormal protein that drives chronic myeloid leukemia.

The resulting patient profiles were used to predict BCR::ABL1 molecular-response measurements during the first 12 months of treatment. Importantly, the two trials were analyzed independently using the same pipeline, rather than being merged after extensive batch correction.

Why an immediate signal could be useful

Targeted drugs can alter signaling within minutes or hours, while standard response assessment often takes weeks or months. If an early blood profile reliably forecasts later response, clinicians might eventually intensify monitoring, investigate adherence or consider a different drug before a poor trajectory becomes obvious.

The study also found that treatment effects were not limited to leukemia cells. Immune populations changed in drug-specific ways, suggesting that response biology includes interactions between the cancer and the surrounding immune system. That broader profile may carry information missed by tracking one molecular marker alone.

The study is predictive, not yet prescriptive

The researchers had usable samples from 49 patients in ENEST1st and 32 in NordCML007, fewer than originally planned. Sample handling also required rapid fixation to preserve phosphorylation states. Delays between blood collection and processing across centers could add noise.

Most importantly, the analyses were exploratory endpoints inside earlier trials. The models were not prospectively locked and used to choose therapy. A clinically useful test would need to work on a new patient without normalization against a large research cohort, using a workflow that ordinary laboratories can reproduce.

Before we overstate the result

This study does not show that a three-hour blood test improves survival or should determine which leukemia drug a patient receives. It establishes an association between early single-cell profiles and later molecular response in two relatively small cohorts. Independent prospective validation and predefined clinical thresholds are still required.

Part of a shift toward response-aware cancer care

NewTqnia has previously covered a 189-tumor single-nucleus atlas of colorectal cancer and an early clinical signal against chemotherapy resistance in pancreatic cancer. The new CML study sits between these approaches: it uses deep cell profiling, but asks a directly clinical question about response to an established treatment.

What happens next

The next milestone is a prospective study that freezes the assay and prediction rules before enrollment, processes samples through a practical multicenter workflow, and tests the model on patients who were not part of development. Only then can researchers determine whether the rapid biological readout adds useful information beyond standard risk scores and early molecular monitoring.

Verified topics and entities

Sources and citations3 sources

Published by

N

NewTqnia Health Desk

An institutional editorial team within NewTqnia

A new version of NewTqnia is ready.